PersistenceMarketResearch states that the global autogenous vaccine market will witness a CAGR of more than 4% between 2020 and 2030.
Livestock vaccination and management has become the foundation of majority of herd health programs. With federal regulation, autogenous vaccines are manufactured as per USDA license with stringent quality control processes in line with those applied over OTC vaccines. Autogenous vaccines are being asked for by the animal owners and practicing veterinarians in Hungary, Czech Republic, and several Central European countries.
Autogenous vaccines are being derived from pathogens that are obtained from an animal or individual and used to treat the same individual/animal with analogous rearing chain or epidemiological unit. These vaccines do subvert problems related to mass-produced immunologically charged material. Also, the advantages do stand out as prevention wins over cure.
By strain type, autogenous vaccines state virus strain and bacterial strain. By end-use, it’s veterinary hospitals, veterinary clinics, veterinary research institutes, and others. Out of these veterinary hospitaals, though trending right now, are bound to be superseded by veterinary research institutes in the near future. This could be due to the fact that with increase in occurrences of contagious diseases, the need for extensive research is likely to take the front seat.
Europe and North America continue to be at the forefront with regards to autogenous vaccines. This could be attributed to the exclusive care being taken regarding rearing of livestock. The Asia-Pacific is expected to witness the fastest growth between 2020 and 2030 with increasing awareness regarding a healthy livestock.
The key market participants include Ceva (Ceva Biovac), Dyntec S.R.O., Elanco Animal Health, Phibro Animal Health Corporation, and Boehringer Ingelheim International GmbH. On the developments’ front, Ceva Sante Animale (Ceva), in 2019, acquired IDT Biologika GmbH for consolidating the market position. On the similar lines, Elanco Animal Health, in 2017, did expand the production capacity by going for the other facility in Maine. The objective was market penetration.